Erbitux Revised Deal Puts Bristol In Charge Of ImClone’s FDA Discussions

Bristol is assuming leadership of ImClone's discussions with FDA regarding resubmission of its colorectal cancer treatment Erbitux according to a revised agreement between the two companies